Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

Jump in the fire — heat shock proteins and their impact on ovarian cancer therapy

(2016) M.B. Stope et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

DNA2 drives processing and restart of reversed replication forks in human cells

(2015) Saravanabhavan Thangavel et al.   JOURNAL OF CELL BIOLOGY

BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks

(2015) Martin R. Higgs et al.   MOLECULAR CELL

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

(2015) E. M. Alexandrova et al.   NATURE

Exploiting replicative stress to treat cancer

(2015) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise

(2014) D. A. Proia et al.   CANCER RESEARCH

Preventing over-resection by DNA2 helicase/nuclease suppresses repair defects in Fanconi anemia cells

(2014) Kenneth K Karanja et al.   CELL CYCLE

Targeting tumour-supportive cellular machineries in anticancer drug development

(2014) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

(2013) H. Liu et al.   CLINICAL CANCER RESEARCH

Lagging strand maturation factor Dna2 is a component of the replication checkpoint initiation machinery

(2013) S. Kumar et al.   GENES & DEVELOPMENT

Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair

(2013) C Barckhausen et al.   ONCOGENE

Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity

(2013) F. Kopper et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

The Intra-S Phase Checkpoint Targets Dna2 to Prevent Stalled Replication Forks from Reversing

(2012) Jiazhi Hu et al.   CELL

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression

(2012) Ramona Schulz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin

(2012) Céline Jacquemont et al.   Molecular Cancer

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

(2012) S. R. Stecklein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions

(2011) Mari Bunkholt Elstrand et al.   HUMAN PATHOLOGY

Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins

(2011) Yun Jeong Kim et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation

(2011) Yisheng Jiao et al.   Molecular Cancer

Hsp90 Inhibitor-Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage

(2011) K. Ha et al.   MOLECULAR CANCER THERAPEUTICS

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction

(2010) L Stingl et al.   BRITISH JOURNAL OF CANCER

Heat Shock Protein 90 Inhibition Depletes LATS1 and LATS2, Two Regulators of the Mammalian Hippo Tumor Suppressor Pathway

(2010) C. J. Huntoon et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

DNA end resection by Dna2–Sgs1–RPA and its stimulation by Top3–Rmi1 and Mre11–Rad50–Xrs2

(2010) Petr Cejka et al.   NATURE

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

(2010) Mikko Taipale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

(2008) Udai Banerji et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair

(2008) T. T. Koll et al.   MOLECULAR CANCER THERAPEUTICS